Physician profile

Roberto Salvatori

Endocrinology, Diabetes & Metabolism · Baltimore, MD

NPI 1063444529

$53,268.06

in general payments reported to CMS, 2019-2025

15 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$14,684.09
Honoraria$4,895.00
Travel and Lodging$2,878.40
Food and Beverage$686.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $24,017.36 2019-2023 Norditropin
Amryt Pharma Holdings LTD $7,926.02 2023 Mycapssa
Chiesi USA, INC. $5,993.18 2024 Mycapssa
Ipsen Biopharmaceuticals, INC $3,440.00 2021
Ascendis Pharma Endocrinology INC $3,376.00 2023
Recordati_rare_diseases_inc. $3,093.93 2021-2022
Hra Pharma Rare Diseases $2,000.00 2021
Strongbridge US INC. $1,800.00 2020
H. Lundbeck A S $1,500.00 2023
Corcept Therapeutics $121.57 2019

5 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roberto Salvatori

$53,268.06

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/320765/roberto-salvatori

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.